Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

about

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

Item

http://www.wikidata.org/entity/Q48118247

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

@en

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

@nl

type

Item

label

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

@en

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

@nl

prefLabel

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

@en

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

@nl

P1476

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

@en

P2093

Edoardo Bruno Vicenzi

http://www.w3.org/2001/XMLSchema#string

Elisabetta Calore

http://www.w3.org/2001/XMLSchema#string

Francesca Carraro

http://www.w3.org/2001/XMLSchema#string

Gloria Tridello

http://www.w3.org/2001/XMLSchema#string

Katia Perruccio

http://www.w3.org/2001/XMLSchema#string

Maria Caterina Putti

http://www.w3.org/2001/XMLSchema#string

Mariadelfina Molinaro

http://www.w3.org/2001/XMLSchema#string

Massimo Berger

http://www.w3.org/2001/XMLSchema#string

Nunzia Decembrino

http://www.w3.org/2001/XMLSchema#string

Sara Rossin

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.

Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.

Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Diagnostic Performance of Galactomannan Antigen Testing in Cerebrospinal Fluid.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

P31

scholarly article

P356

10.1111/EJH.13017

http://www.w3.org/2001/XMLSchema#string

P50

Simone Cesaro

P577

2017-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29240266

http://www.w3.org/2001/XMLSchema#string